The specter of generic rivalry has long loomed around copyright’s blockbuster drug, PDE5 Inhibitor, triggering questions about the prospects of similar drug investments. While first times saw impressive profits, the exclusivity lapse has created the way for discounted alternatives, possibly reducing profitability and posing a real hazard for inve